dexamethasone + NK-1 receptor antagonist + 5-HT3 receptor antagonist

The combination of dexamethasone, NK-1 receptor antagonist, and 5-HT3 receptor antagonist is a triple antiemetic regimen widely used for preventing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea and vomiting (PONV). ## Description This triple antiemetic combination represents a standard of care for preventing nausea and vomiting, particularly in patients receiving highly emetogenic chemotherapy (HEC) or moderately emetogenic chemotherapy (MEC). Each component targets different pathways involved in the emetic response: - **Dexamethasone**: A corticosteroid that reduces inflammation and may affect multiple pathways involved in nausea and vomiting. - **NK-1 receptor antagonists** (such as aprepitant, rolapitant, or netupitant): Block substance P from binding to neurokinin-1 receptors in both the gut and central nervous system. - **5-HT3 receptor antagonists** (such as ondansetron, granisetron, or palonosetron): Block serotonin from binding to 5-HT3 receptors in the gastrointestinal tract and chemoreceptor trigger zone. Clinical studies have consistently shown that this triple combination provides superior control of both acute and delayed CINV compared to dual combinations or single agents[1][3][5][7]. The combination is particularly effective in the delayed phase of CINV and has demonstrated significant benefits in patients receiving moderately emetogenic chemotherapy[5][6]. ## Specific Combinations Several specific formulations of this triple combination exist: - **NEPA + dexamethasone**: A fixed-dose combination of netupitant (NK-1 antagonist) and palonosetron (5-HT3 antagonist) plus dexamethasone has shown superior efficacy compared to other NK-1 antagonist-based regimens in multiple clinical trials[5]. - **Rolapitant + 5-HT3 antagonist + dexamethasone**: This combination has demonstrated improved control of CINV compared to 5-HT3 antagonist plus dexamethasone alone[7]. - **Aprepitant + 5-HT3 antagonist + dexamethasone (ADH)**: Studies have shown this combination achieves better overall complete response rates and lower rates of rescue antiemetic treatment compared to dual therapy[3]. ## Clinical Applications This triple combination is recommended by major clinical guidelines for: - Prevention of CINV in patients receiving highly emetogenic chemotherapy - Prevention of CINV in patients receiving moderately emetogenic chemotherapy - Some cases of postoperative nausea and vomiting In certain situations, dexamethasone-sparing approaches may be considered, particularly when a patient's exposure to corticosteroids must be limited due to comorbidities or patient preference[4].

Other names

triple antiemetic combinationtriple antiemetic regimentriple antiemetic therapy